18.47

3.82% 0.68

After Hours: 18.36 -0.11 -0.60%

Definium Therapeutics Inc (DFTX)

Overview News Price History Discussions Forecast

Definium Therapeutics Inc stock is traded at $18.47, with a volume of 2.48M. It is up +3.82% in the last 24 hours and up +4.82% over the past month. Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Previous Close:

$17.79

Open:

$17.87

24h Volume:

2.48M

Relative Volume:

2.08

Market Cap:

$1.84B

Revenue:

Net Income/Loss:

$-183.79M

P/E Ratio:

-8.9266

EPS:

-2.0691

Net Cash Flow:

$-131.84M

1W Performance:

+4.71%

1M Performance:

+4.82%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$17.82

$19.06

1-Week Range:

$17.25

$19.67

52-Week Range:

$14.62

$19.67

Definium Therapeutics Inc Stock (DFTX) Company Profile

Name

Definium Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

212-220-6633

Address

ONE WORLD TRADE CENTER, NEW YORK

Employee

106

Twitter

Next Earnings Date

Latest SEC Filings

DFTX's Discussions on Twitter

Compare DFTX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DFTX Definium Therapeutics Inc	18.47	1.77B	0	-183.79M	-131.84M	-2.0691
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-30-26	Initiated	Jefferies	Buy
Oct-13-25	Initiated	Needham	Buy
Aug-04-25	Resumed	Oppenheimer	Outperform
Jan-28-25	Initiated	Evercore ISI	Outperform
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Jul-24-24	Initiated	ROTH MKM	Buy
May-29-24	Initiated	Robert W. Baird	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform
Dec-05-23	Initiated	Canaccord Genuity	Buy
Dec-09-22	Resumed	ROTH Capital	Buy
Nov-16-22	Initiated	RBC Capital Mkts	Outperform
Aug-26-22	Initiated	Oppenheimer	Outperform
Aug-10-22	Initiated	Cantor Fitzgerald	Overweight
May-04-22	Initiated	ROTH Capital	Buy
Jun-28-21	Initiated	Maxim Group	Buy

View All

Definium Therapeutics Inc Stock (DFTX) Latest News

Mar 25, 2026

A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum - Yahoo Finance

Mar 25, 2026